SG10201900514RA - Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors - Google Patents
Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitorsInfo
- Publication number
- SG10201900514RA SG10201900514RA SG10201900514RA SG10201900514RA SG10201900514RA SG 10201900514R A SG10201900514R A SG 10201900514RA SG 10201900514R A SG10201900514R A SG 10201900514RA SG 10201900514R A SG10201900514R A SG 10201900514RA SG 10201900514R A SG10201900514R A SG 10201900514RA
- Authority
- SG
- Singapore
- Prior art keywords
- kinase inhibitors
- pyrimidine compounds
- trk kinase
- substituted pyrazolo
- trk
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/02—Ergot alkaloids of the cyclic peptide type
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS Compounds of Formula (I) in which R 1, R 2, R 3, R 4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor. Figure: None
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10761608P | 2008-10-22 | 2008-10-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201900514RA true SG10201900514RA (en) | 2019-02-27 |
Family
ID=41328903
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2014004790A SG196855A1 (en) | 2008-10-22 | 2009-10-21 | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
SG10201914059WA SG10201914059WA (en) | 2008-10-22 | 2009-10-21 | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
SG10201900514RA SG10201900514RA (en) | 2008-10-22 | 2009-10-21 | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2014004790A SG196855A1 (en) | 2008-10-22 | 2009-10-21 | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
SG10201914059WA SG10201914059WA (en) | 2008-10-22 | 2009-10-21 | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
Country Status (39)
Country | Link |
---|---|
US (10) | US8513263B2 (en) |
EP (4) | EP2725028B1 (en) |
JP (5) | JP5600111B2 (en) |
KR (5) | KR101634833B1 (en) |
CN (2) | CN102264736B (en) |
AR (2) | AR074052A1 (en) |
AU (1) | AU2009308465B2 (en) |
BR (1) | BRPI0919873B8 (en) |
CA (1) | CA2741313C (en) |
CL (1) | CL2011000880A1 (en) |
CO (1) | CO6440551A2 (en) |
CR (1) | CR20110261A (en) |
CY (4) | CY1118199T1 (en) |
DK (4) | DK3372605T3 (en) |
ES (4) | ES2456346T3 (en) |
HK (2) | HK1160640A1 (en) |
HR (3) | HRP20211722T1 (en) |
HU (4) | HUE057625T2 (en) |
IL (3) | IL212341A0 (en) |
LT (4) | LT2725028T (en) |
LU (1) | LUC00150I2 (en) |
ME (1) | ME03010B (en) |
MX (1) | MX2011004204A (en) |
MY (1) | MY169791A (en) |
NL (1) | NL301033I2 (en) |
NO (2) | NO3106463T3 (en) |
NZ (1) | NZ592809A (en) |
PL (4) | PL3372605T3 (en) |
PT (4) | PT2350071E (en) |
RS (3) | RS62869B1 (en) |
RU (2) | RU2523544C2 (en) |
SG (3) | SG196855A1 (en) |
SI (4) | SI2350071T1 (en) |
SM (1) | SMT201400153B (en) |
TR (1) | TR201807039T4 (en) |
TW (4) | TWI577680B (en) |
UA (1) | UA106054C2 (en) |
UY (1) | UY32192A (en) |
WO (1) | WO2010048314A1 (en) |
Families Citing this family (133)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2464461T3 (en) | 2008-09-22 | 2014-06-02 | Array Biopharma, Inc. | Imidazo [1,2B] pyridazine compounds substituted as inhibitors of TRK kinase |
KR101634833B1 (en) * | 2008-10-22 | 2016-06-29 | 어레이 바이오파마 인크. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
AR077468A1 (en) * | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
TWI510487B (en) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
EP2918588B1 (en) | 2010-05-20 | 2017-05-03 | Array Biopharma, Inc. | Macrocyclic compounds as TRK kinase inhibitors |
UY33597A (en) | 2010-09-09 | 2012-04-30 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK |
WO2012034095A1 (en) * | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
CN103492384B (en) * | 2011-02-25 | 2016-05-11 | 诺华股份有限公司 | As compound and the composition of TRK inhibitor |
DK2712358T3 (en) * | 2011-05-13 | 2017-02-06 | Array Biopharma Inc | PYRROLIDINYLUREA, PYRROLIDINYLTHIOUREA AND PYRROLIDINYLGUANIDE IN COMPOUNDS AS TRKA-KINASE INHIBITORS |
CN104114553B (en) * | 2011-12-12 | 2017-03-01 | 雷迪博士实验室有限公司 | Substituted pyrazolo [1,5 a] pyridine as tropomyosin receptor kinase (Trk) inhibitor |
TR201808280T4 (en) * | 2012-03-09 | 2018-07-23 | Lexicon Pharmaceuticals Inc | Pyrazolo [1,5-a] pyrimidine-based compounds, compositions containing them, and methods of use. |
WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9981959B2 (en) | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9828360B2 (en) | 2012-11-13 | 2017-11-28 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
PT2922844T (en) | 2012-11-13 | 2018-04-02 | Array Biopharma Inc | N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
LT2920166T (en) | 2012-11-13 | 2016-12-12 | Array Biopharma, Inc. | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain |
US9969694B2 (en) | 2012-11-13 | 2018-05-15 | Array Biopharma Inc. | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078417A1 (en) * | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078408A1 (en) * | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9546156B2 (en) | 2012-11-13 | 2017-01-17 | Array Biopharma Inc. | N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014110574A1 (en) | 2013-01-14 | 2014-07-17 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
EP3670506B1 (en) | 2013-01-15 | 2023-01-04 | Incyte Holdings Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
EA201690458A1 (en) | 2013-08-23 | 2016-07-29 | Инсайт Корпорейшн | FURO- AND THYENOPYRIDINCARBOXAMIDES USED AS PIM-KINASE INHIBITORS |
TW201542550A (en) * | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use |
EP3636650A1 (en) | 2014-01-24 | 2020-04-15 | Turning Point Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
BR112016018062B1 (en) * | 2014-02-07 | 2022-11-16 | Exithera Pharmaceuticals Inc | THERAPEUTIC COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES |
US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
WO2015143654A1 (en) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
KR101998461B1 (en) | 2014-05-15 | 2019-07-09 | 어레이 바이오파마 인크. | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
HUE061448T2 (en) * | 2014-11-16 | 2023-07-28 | Array Biopharma Inc | Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
KR102595599B1 (en) | 2014-12-02 | 2023-11-02 | 이그니타, 인코포레이티드 | Combinations for the treatment of neuroblastoma |
WO2016097869A1 (en) | 2014-12-15 | 2016-06-23 | Cmg Pharmaceutical Co., Ltd. | Fused ring heteroaryl compounds and their use as trk inhibitors |
US10329294B2 (en) | 2015-03-12 | 2019-06-25 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of IRAK4 activity |
US10155765B2 (en) | 2015-03-12 | 2018-12-18 | Merck Sharp & Dohme Corp. | Carboxamide inhibitors of IRAK4 activity |
WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
AU2016270321B2 (en) * | 2015-05-29 | 2020-09-10 | Ignyta, Inc. | Compositions and methods for treating patients with RTK mutant cells |
PE20180329A1 (en) * | 2015-06-01 | 2018-02-13 | Loxo Oncology Inc | METHODS TO DIAGNOSE AND TREAT CANCER |
JP6871903B2 (en) | 2015-07-02 | 2021-05-19 | ターニング・ポイント・セラピューティクス・インコーポレイテッドTurning Point Therapeutics,Inc. | Chiral diallyl macrocyclic molecule as a modulator of protein kinase |
CN113354653A (en) | 2015-07-06 | 2021-09-07 | 特普医药公司 | Diaryl macrocyclic polymorphs and methods of making the same |
CN108349969B (en) | 2015-07-16 | 2022-05-10 | 阵列生物制药公司 | Substituted pyrazolo [1,5-a ] pyridine compounds as RET kinase inhibitors |
RU2728579C2 (en) | 2015-07-21 | 2020-07-30 | Тёрнинг Поинт Терапьютикс, Инк. | Chiral diaryl macrocycles and use thereof |
WO2017035354A1 (en) | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
AR105967A1 (en) | 2015-09-09 | 2017-11-29 | Incyte Corp | SALTS OF A PIM QUINASA INHIBITOR |
TW201718546A (en) | 2015-10-02 | 2017-06-01 | 英塞特公司 | Heterocyclic compounds useful as PIM kinase inhibitors |
TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
AR106756A1 (en) | 2015-11-19 | 2018-02-14 | Blueprint Medicines Corp | USEFUL COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NTRK-RELATED DISORDERS |
CN108697661A (en) | 2015-12-18 | 2018-10-23 | 亚尼塔公司 | Combination for treating cancer |
BR112018070017A2 (en) * | 2016-04-04 | 2019-02-05 | Loxo Oncology Inc | Pediatric Cancer Treatment Methods |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
JP7061602B2 (en) | 2016-04-04 | 2022-04-28 | ロクソ オンコロジー, インコーポレイテッド | (S) -N- (5-((R) -2- (2,5-difluorophenyl) -pyrrolidin-1-yl) -pyrazolo [1,5-a] pyrimidin-3-yl) -3-hydroxy Liquid formulation of pyrrolidine-1-carboxamide |
WO2017201241A1 (en) * | 2016-05-18 | 2017-11-23 | Mark Reynolds | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide |
JP2019527230A (en) | 2016-07-28 | 2019-09-26 | ターニング・ポイント・セラピューティクス・インコーポレイテッドTurning Point Therapeutics,Inc. | Macrocyclic kinase inhibitor |
TWI704148B (en) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
JOP20190077A1 (en) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
JOP20190092A1 (en) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF |
CN108003161B (en) * | 2016-10-28 | 2020-10-09 | 正大天晴药业集团股份有限公司 | Neurotrophic factor tyrosine kinase receptor inhibitors |
CN109890820B (en) * | 2016-10-28 | 2020-11-03 | 正大天晴药业集团股份有限公司 | Aminopyrazolopyrimidine compounds as neurotrophin tyrosine kinase receptor inhibitors |
AR110252A1 (en) | 2016-11-30 | 2019-03-13 | Gilead Sciences Inc | FUSIONED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF THE QUINASA CAM |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
JP6888101B2 (en) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | Substituted pyrazolo [1,5-a] pyrazine compounds as RET kinase inhibitors |
TWI808958B (en) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | Combination therapy involving diaryl macrocyclic compounds |
JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
EP3654952A1 (en) | 2017-07-19 | 2020-05-27 | Ignyta, Inc. | Pharmaceutical compositions comprising entrectinib |
CA3069232A1 (en) | 2017-07-28 | 2019-01-31 | Turning Point Therapeutics, Inc. | Macrocyclic compounds and uses thereof |
ES2930081T3 (en) * | 2017-08-11 | 2022-12-07 | Teligene Ltd | Substituted Pyrazolopyrimidines Useful as Kinase Inhibitors |
US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
KR102619444B1 (en) * | 2017-08-23 | 2023-12-29 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical compositions and uses thereof |
CN107556226B (en) * | 2017-09-21 | 2020-06-30 | 苏州明锐医药科技有限公司 | Preparation method of Latricinib intermediate |
CN107445879B (en) * | 2017-09-21 | 2020-07-24 | 苏州立新制药有限公司 | Preparation method of Latricinib intermediate |
TWI791053B (en) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof |
TWI812649B (en) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
EP3697390A1 (en) | 2017-10-17 | 2020-08-26 | Ignyta, Inc. | Pharmaceutical compositions and dosage forms |
EP3700576A1 (en) | 2017-10-26 | 2020-09-02 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
WO2019089668A1 (en) | 2017-10-31 | 2019-05-09 | Teva Pharmaceuticals Usa, Inc. | Salts and solid state forms of larotrectinib |
AU2018364938B2 (en) * | 2017-11-10 | 2021-11-11 | Angex Pharmaceutical, Inc. | Macrocyclic compounds as TRK kinase inhibitors and uses thereof |
CN107987082B (en) * | 2017-11-14 | 2019-09-20 | 苏州东南药业股份有限公司 | A kind of Preparation Method And Their Intermediate of Larotrectinib |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
US11230546B2 (en) * | 2017-12-15 | 2022-01-25 | Pyramid Biosciences, Inc | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer |
PL3728271T3 (en) | 2017-12-19 | 2023-01-23 | Turning Point Therapeutics, Inc. | Macrocyclic compounds for treating diseases |
WO2019120194A1 (en) * | 2017-12-22 | 2019-06-27 | 深圳市塔吉瑞生物医药有限公司 | Substituted pyrazolo[1,5-a]pyrimidine compound and pharmaceutical composition and use thereof |
TWI802635B (en) | 2018-01-18 | 2023-05-21 | 美商亞雷生物製藥股份有限公司 | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
US11345703B2 (en) | 2018-01-23 | 2022-05-31 | Shenzhen Targetrx, Inc. | Substituted pyrazolo[1,5-a]pyrimidine macrocyclic compound |
TW201932472A (en) * | 2018-01-30 | 2019-08-16 | 大陸商上海吉倍生物技術有限公司 | Compound having macrocyclic molecular structure and use thereof |
WO2019174598A1 (en) * | 2018-03-14 | 2019-09-19 | Fochon Pharmaceuticals, Ltd. | SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-a] PYRIMIDINE AND IMIDAZO [1, 2-b] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS |
CN110305138B (en) * | 2018-03-27 | 2021-04-23 | 海创药业股份有限公司 | Compound for treating cancer and application thereof |
US20210023086A1 (en) | 2018-03-29 | 2021-01-28 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
JP7328212B2 (en) | 2018-03-30 | 2023-08-16 | 住友重機械工業株式会社 | Driving support system for construction machinery, construction machinery |
EP3786167A4 (en) | 2018-04-25 | 2021-06-09 | Primegene (Beijing) Co., Ltd. | Diaryl macrocyclic compound and pharmaceutical composition, and use thereof |
CN110294761B (en) * | 2018-06-08 | 2020-09-08 | 南京雷正医药科技有限公司 | Substituted pyrazolo [1,5-a ] pyrimidine compounds as Trk kinase inhibitors |
CN110627812B (en) * | 2018-06-25 | 2022-10-11 | 北京诺诚健华医药科技有限公司 | Heterocyclic compounds as TRK inhibitors |
KR102545594B1 (en) | 2018-07-31 | 2023-06-21 | 록쏘 온콜로지, 인코포레이티드 | (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl Spray-dried dispersions and formulations of )-1H-pyrazole-4-carboxamide |
WO2020037004A1 (en) | 2018-08-14 | 2020-02-20 | Osteoqc Inc. | Pyrrolo - dipyridine compounds |
US11903949B2 (en) | 2018-08-14 | 2024-02-20 | Ossifi Therapeutics Llc | Fluoro beta-carboline compounds |
CN110857304B (en) * | 2018-08-24 | 2021-05-18 | 北京富龙康泰生物技术有限公司 | Trk inhibitor, preparation method and application thereof |
CN112739691B (en) | 2018-09-03 | 2023-05-23 | 泰励生物科技(上海)有限公司 | TRK inhibitors as anticancer agents |
JP2022500383A (en) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Condensed heterocyclic compound as a RET kinase inhibitor |
US20210403485A1 (en) * | 2018-09-29 | 2021-12-30 | Shandong Luye Pharmaceutical Co., Ltd. | Pyrazolopyrimidine derivative as selective trk inhibitor |
CN111039947A (en) * | 2018-10-15 | 2020-04-21 | 上海轶诺药业有限公司 | Preparation and application of protein receptor kinase inhibitor |
CN111171019A (en) | 2018-11-13 | 2020-05-19 | 上海轶诺药业有限公司 | Five-membered and six-membered heterocyclic compounds and application thereof as protein receptor kinase inhibitors |
CN111171020A (en) | 2018-11-13 | 2020-05-19 | 上海轶诺药业有限公司 | Hexa-membered and hexa-membered heterocyclic compounds and application thereof as protein receptor kinase inhibitors |
CN109232582B (en) * | 2018-11-28 | 2021-02-05 | 安礼特(上海)医药科技有限公司 | Crystalline form of ralotinib bisulfate, preparation and application thereof |
CN111269233A (en) * | 2018-12-05 | 2020-06-12 | 上海轶诺药业有限公司 | Preparation and application of imidazo aromatic ring compounds |
CN109608464B (en) * | 2018-12-12 | 2021-09-24 | 上海健康医学院 | Radioiodine-labeled Larotrectinib compound and preparation method and application thereof |
CN109705124B (en) * | 2018-12-14 | 2021-09-24 | 上海健康医学院 | Radioactive fluorine labeled Larotrectinib compound and preparation method thereof |
EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
US20220041579A1 (en) | 2018-12-19 | 2022-02-10 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of fgfr tyrosine kinases |
CN111362946A (en) * | 2018-12-25 | 2020-07-03 | 上海度德医药科技有限公司 | Pharmaceutical compound and composition and application thereof |
CN109942574B (en) * | 2019-01-11 | 2022-04-01 | 成都阿奇生物医药科技有限公司 | Tianqitinib and preparation method and application thereof |
CN109942582B (en) * | 2019-03-15 | 2020-12-01 | 上海健康医学院 | PET (positron emission tomography) probe of targeted tropomyosin kinase TRK fusion protein as well as synthesis and application of PET probe |
WO2020187291A1 (en) | 2019-03-19 | 2020-09-24 | 华中师范大学 | Pyrazolopyrimidine compound, pharmaceutical composition, and application therefor |
CN114364798A (en) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | Combination of Dbait molecules with kinase inhibitors for the treatment of cancer |
CN111848626B (en) * | 2019-04-30 | 2021-11-30 | 江苏柯菲平医药股份有限公司 | TRK kinase inhibitor and application thereof |
US20200398978A1 (en) * | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
CA3145641A1 (en) * | 2019-08-08 | 2021-02-11 | Didier Rognan | Trkb positive allosteric modulators |
CN110804059B (en) * | 2019-09-30 | 2024-03-12 | 郑州泰基鸿诺医药股份有限公司 | Carbamate compound, pharmaceutical composition and application thereof |
CN110643672A (en) * | 2019-10-15 | 2020-01-03 | 西安交通大学 | Medical application of high-expression TrkB as novel target point in inhibiting pancreatic cancer metastasis |
AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
CN112812118A (en) * | 2019-11-18 | 2021-05-18 | 上海轶诺药业有限公司 | Preparation and application of protein receptor kinase inhibitor |
CN111138437B (en) * | 2019-12-04 | 2021-03-05 | 杭州华东医药集团新药研究院有限公司 | Substituted pyrazolo [1,5-a ] pyrimidine amino acid derivatives and uses thereof |
CN112979654B (en) * | 2019-12-16 | 2024-03-19 | 赛诺哈勃药业(成都)有限公司 | Heteroaryl fused ring compounds, preparation method and application thereof |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2021187878A1 (en) * | 2020-03-17 | 2021-09-23 | 제이투에이치바이오텍 주식회사 | Compound for inhibiting mutagenic trk fusion protein, and pharmaceutical use and manufacturing method thereof |
CN113563343B (en) * | 2020-07-27 | 2022-05-24 | 杭州邦顺制药有限公司 | Substituted pyrazolo [1,5-a ] pyrimidine compounds and uses thereof |
WO2022168115A1 (en) | 2021-02-05 | 2022-08-11 | Mylan Laboratories Limited | A process for the preparation of larotrectinib or its salts |
WO2023083357A1 (en) * | 2021-11-15 | 2023-05-19 | 石药集团中奇制药技术(石家庄)有限公司 | Salt of nitrogen-containing fused heterocyclic amide compound, crystal form thereof, and use thereof |
CN116003469B (en) * | 2022-03-23 | 2023-10-17 | 南京知和医药科技有限公司 | Preparation and use methods of pyrimidinyl antiviral compounds |
CN114907315B (en) * | 2022-05-17 | 2023-09-12 | 重庆医科大学 | Synthesis method of Selitretinib intermediate |
WO2024023836A1 (en) | 2022-07-27 | 2024-02-01 | Mylan Laboratories Limited | Polymorphic form of larotrectinib sulfate |
Family Cites Families (201)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1017286A (en) | 1909-03-01 | 1912-02-13 | Du Pont Powder Co | Apparatus for treating explosive powder. |
US1001160A (en) | 1910-04-05 | 1911-08-22 | Paul A Otto | Aerodrome. |
US1004709A (en) | 1910-05-20 | 1911-10-03 | Albert E Yerkes | Spraying device. |
US1013712A (en) | 1911-06-03 | 1912-01-02 | Alfred D Williams | Tie and rail-fastener. |
NZ234143A (en) | 1989-06-28 | 1991-10-25 | Mcneil Ppc Inc | Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents |
GB9212308D0 (en) | 1992-06-10 | 1992-07-22 | Ici Plc | Therapeutic compositions |
RU2139281C1 (en) | 1993-11-30 | 1999-10-10 | Джи Ди Сирл энд Компани | Pyrazolyl-substituted benzenesulfoneamide or its pharmaceutically acceptable salt, method of treatment of patients with inflammation or inflammation-associated diseases |
US5430021A (en) | 1994-03-18 | 1995-07-04 | Pharmavene, Inc. | Hydrophobic drug delivery systems |
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US5844092A (en) | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
US6458811B1 (en) | 1996-03-26 | 2002-10-01 | Eli Lilly And Company | Benzothiophenes formulations containing same and methods |
CA2206201A1 (en) | 1996-05-29 | 1997-11-29 | Yoshiaki Isobe | Pyrazole derivatives and their pharmaceutical use |
JPH1020683A (en) | 1996-07-05 | 1998-01-23 | Fuji Xerox Co Ltd | Image forming device |
JP3898296B2 (en) * | 1996-08-28 | 2007-03-28 | ポーラ化成工業株式会社 | Pyrrolopyrazolopyrimidine compounds and pharmaceuticals containing the same as active ingredients |
CA2285264A1 (en) | 1997-04-25 | 1998-11-05 | Michiyo Gyoten | Condensed pyridazine derivatives, their production and use |
PL195280B1 (en) | 1999-01-21 | 2007-08-31 | Bristol Myers Squibb Co | Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6534085B1 (en) | 1999-09-23 | 2003-03-18 | Bioresponse L.L.C. | Phytochemicals for promoting weight loss |
WO2001098361A2 (en) | 2000-06-22 | 2001-12-27 | Genentech, Inc. | Agonist anti-trk-c monoclonal antibodies |
GB0028575D0 (en) | 2000-11-23 | 2001-01-10 | Elan Corp Plc | Oral pharmaceutical compositions containing cyclodextrins |
BR0116388A (en) | 2000-12-22 | 2003-09-30 | Astrazeneca Ab | Compound, process for preparing a compound, pharmaceutical composition and method for treating feeding disorders and use of a compound in a warm-blooded animal |
TWI312347B (en) | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
KR20040049829A (en) | 2001-05-30 | 2004-06-12 | 제넨테크, 인크. | Anti-ngf antibodies for the treatment of various disorders |
US7101572B2 (en) | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
GB0207249D0 (en) * | 2002-03-27 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
US7662826B2 (en) | 2002-04-23 | 2010-02-16 | Shionogi & Co., Ltd. | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same |
US7449488B2 (en) * | 2002-06-04 | 2008-11-11 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
JP4024624B2 (en) | 2002-08-26 | 2007-12-19 | 富士通株式会社 | Semiconductor device manufacturing method and manufacturing apparatus |
US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
KR101088922B1 (en) * | 2002-09-04 | 2011-12-01 | 파마코페이아, 엘엘씨. | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors |
US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
AU2003298942A1 (en) | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
WO2004052315A2 (en) | 2002-12-11 | 2004-06-24 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
GB0303910D0 (en) * | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
US20070037150A1 (en) | 2003-02-21 | 2007-02-15 | The Johns Hopkins University | Tyrosine kinome |
JP2004277337A (en) | 2003-03-14 | 2004-10-07 | Sumitomo Pharmaceut Co Ltd | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE |
EP1608652A1 (en) * | 2003-03-31 | 2005-12-28 | Vernalis (Cambridge) Limited | Pyrazolopyrimidine compounds and their use in medicine |
EP1615667A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist |
US20060094699A1 (en) | 2003-04-11 | 2006-05-04 | Kampen Gita Camilla T | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
WO2004089471A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
WO2004096851A1 (en) | 2003-04-28 | 2004-11-11 | Galpharma Co., Ltd. | Galectin 9-inducing factor |
PA8603801A1 (en) | 2003-05-27 | 2004-12-16 | Janssen Pharmaceutica Nv | DERIVATIVES OF QUINAZOLINE |
JP2005008581A (en) | 2003-06-20 | 2005-01-13 | Kissei Pharmaceut Co Ltd | NEW PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME AND APPLICATION THEREOF |
EA009517B1 (en) * | 2003-06-27 | 2008-02-28 | Байер Кропсайенс Аг | Pyrazolopyrimidines |
NZ544751A (en) | 2003-07-15 | 2009-05-31 | Amgen Inc | Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors |
US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
DE602004012891T2 (en) | 2003-12-18 | 2009-04-09 | Janssen Pharmaceutica N.V. | PYRIDO AND PYRIMIDOPYRIMIDIN DERIVATIVES AS ANTI-PROLIFERATIVE AGENTS |
WO2005099363A2 (en) | 2004-03-26 | 2005-10-27 | Whitehead Institute For Biomedical Research | Methods of diagnosing, preventing and treating cancer metastasis |
CN1938311A (en) | 2004-03-30 | 2007-03-28 | 因特蒙公司 | Macrocyclic compounds as inhibitors of viral replication |
JO3088B1 (en) | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | Macrocyclic Quinazoline derivatives and their use as MTKI |
DE102005003687A1 (en) | 2005-01-26 | 2006-07-27 | Sphingo Tec Gmbh | Immunodiagnostic determination of neurotensin in mammal blood, comprises injecting immune active N-terminal mammal proneurotensin in to the serum- or plasma- sample |
ES2347172T3 (en) * | 2005-02-16 | 2010-10-26 | Astrazeneca Ab | CHEMICAL COMPOUNDS. |
CN101119996A (en) * | 2005-02-16 | 2008-02-06 | 阿斯利康(瑞典)有限公司 | Chemical compouns |
SI1869049T1 (en) | 2005-03-21 | 2009-08-31 | Lilly Co Eli | Imidazopyridazine compounds |
EP1877057A1 (en) * | 2005-04-27 | 2008-01-16 | AstraZeneca AB | Use of pyrazolyl-pyrimidine derivatives in the treatment of pain |
MX2007014328A (en) | 2005-05-16 | 2008-02-12 | Astrazeneca Ab | Chemical compounds. |
CN100406650C (en) | 2005-06-05 | 2008-07-30 | 徐斌 | Modular comb type expansion joint installation of girder capable of resisting super displacement |
ITRM20050290A1 (en) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS. |
US20070025540A1 (en) | 2005-07-07 | 2007-02-01 | Roger Travis | Call center routing based on talkativeness |
NZ594105A (en) | 2005-07-25 | 2013-02-22 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
EP1910369A1 (en) * | 2005-07-29 | 2008-04-16 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
WO2007019058A1 (en) | 2005-08-03 | 2007-02-15 | Eastman Chemical Company | Tocopheryl polyethylene glycol succinate powder and process for preparing same |
US20070191306A1 (en) | 2005-08-17 | 2007-08-16 | Bristol-Myers Squibb Company | FACTOR Xa INHIBITOR FORMULATION AND METHOD |
EP1926734A1 (en) | 2005-08-22 | 2008-06-04 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
PL1919979T5 (en) | 2005-08-25 | 2017-10-31 | Creabilis Therapeutics Spa | Polymer conjugates of k-252a and derivatives thereof |
WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
DE102005042742A1 (en) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituted imidazo [1,2b] pyridazines as kinase inhibitors, their production and use as pharmaceuticals |
US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
JP5152922B2 (en) * | 2005-10-06 | 2013-02-27 | メルク・シャープ・アンド・ドーム・コーポレーション | Use of pyrazolo [1,5-A] pyrimidine derivatives to inhibit protein kinases and methods for inhibiting protein kinases |
EP1931675B1 (en) * | 2005-10-06 | 2015-01-14 | Merck Sharp & Dohme Corp. | Pyrazolo(1, 5a) pyrimidines as protein kinase inhibitors |
WO2007057782A2 (en) | 2005-10-11 | 2007-05-24 | Centre National De La Recherche Scientifique (Cnrs) | 3 -hydroxyflavone derivatives for the detection and the quantification of cell apoptosis |
WO2007044893A2 (en) | 2005-10-11 | 2007-04-19 | Intermune, Inc. | Compounds and methods for inhibiting hepatitis c viral replication |
US8101625B2 (en) | 2005-10-21 | 2012-01-24 | Exelixis, Inc. | Pyrimidinones as Casein Kinase II (CK2) modulators |
GB0524436D0 (en) | 2005-11-30 | 2006-01-11 | Novartis Ag | Organic compounds |
US20070166336A1 (en) | 2005-12-13 | 2007-07-19 | David Delmarre | Stable and palatable oral liquid sumatriptan compositions |
US20080108611A1 (en) | 2006-01-19 | 2008-05-08 | Battista Kathleen A | Substituted thienopyrimidine kinase inhibitors |
KR100846988B1 (en) | 2006-03-06 | 2008-07-16 | 제일약품주식회사 | Novel thienopyrimidine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same |
US7723330B2 (en) | 2006-03-07 | 2010-05-25 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
GB0606805D0 (en) | 2006-04-04 | 2006-05-17 | Novartis Ag | Organic compounds |
TWI409268B (en) | 2006-04-26 | 2013-09-21 | Hoffmann La Roche | Pharmaceutical compounds |
EP1873157A1 (en) | 2006-06-21 | 2008-01-02 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
TW201345908A (en) | 2006-07-05 | 2013-11-16 | Mitsubishi Tanabe Pharma Corp | A pyrazolo [1,5-a] pyrimidine compound |
US20100029619A1 (en) * | 2006-08-04 | 2010-02-04 | Takeda Pharmaceutical Company Limted | Fused heterocyclic compound |
CA2659971A1 (en) | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
US7531539B2 (en) | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
AU2007292924A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
JP2010504933A (en) * | 2006-09-29 | 2010-02-18 | ノバルティス アーゲー | Pyrazolopyrimidines as PI3K lipid kinase inhibitors |
WO2008052734A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
NZ576234A (en) | 2006-11-06 | 2011-06-30 | Supergen Inc | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
US7820684B2 (en) | 2007-03-01 | 2010-10-26 | Supergen, Inc. | Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same |
US20080234262A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
US20080255153A1 (en) * | 2007-03-28 | 2008-10-16 | Biovitrum Ab (Publ) | New compounds |
JP5374492B2 (en) | 2007-04-03 | 2013-12-25 | アレイ バイオファーマ、インコーポレイテッド | Imidazo [1,2-A] pyridine compounds as receptor tyrosine kinase inhibitors |
MX2009011951A (en) | 2007-05-04 | 2009-12-11 | Irm Llc | Compounds and compositions as c-kit and pdgfr kinase inhibitors. |
AU2008265104B2 (en) | 2007-06-21 | 2013-09-12 | Janssen Pharmaceutica Nv | Indolin-2-ones and aza-indolin-2-ones |
DK2176231T3 (en) | 2007-07-20 | 2016-12-12 | Nerviano Medical Sciences Srl | SUBSTITUTED indazole ACTIVE AS kinase inhibitors |
WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
KR101709488B1 (en) | 2007-08-10 | 2017-02-24 | 리제너론 파아마슈티컬스, 인크. | High affinity human antibodies to human nerve growth factor |
AP2010005234A0 (en) | 2007-10-16 | 2010-04-30 | Wyeth Llc | Thienopyrimidine and pyrazolopyrimidline compoundsand their use as MTOR kinase and P13 kinase inhib itors |
KR20100089851A (en) | 2007-10-23 | 2010-08-12 | 노파르티스 아게 | Use of trkb antibodies for the treatment of respiratory disorders |
EP2217601A1 (en) | 2007-11-08 | 2010-08-18 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyridazines for use as protein kinase inhibitors |
WO2009070567A1 (en) | 2007-11-28 | 2009-06-04 | Schering Corporation | 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
KR101290503B1 (en) | 2008-01-17 | 2013-07-26 | 아이알엠 엘엘씨 | Improved anti-trkb antibodies |
KR101353425B1 (en) | 2008-03-03 | 2014-02-18 | 유씨비 파마, 에스.에이. | Pharmaceutical solutions, process of preparation and therapeutic uses |
KR100963051B1 (en) | 2008-03-14 | 2010-06-09 | 광동제약 주식회사 | Oral solution composition shielding bitterness of sulfodehydroabietic aci with small particle size |
US20090275622A1 (en) | 2008-04-30 | 2009-11-05 | Prasoona Linga | Nizatidine formulations |
CA2722418C (en) * | 2008-05-13 | 2013-09-17 | Irm Llc | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
JP5677296B2 (en) | 2008-07-29 | 2015-02-25 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Use of CDK inhibitors for the treatment of glioma |
ES2464461T3 (en) | 2008-09-22 | 2014-06-02 | Array Biopharma, Inc. | Imidazo [1,2B] pyridazine compounds substituted as inhibitors of TRK kinase |
KR101634833B1 (en) * | 2008-10-22 | 2016-06-29 | 어레이 바이오파마 인크. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
CN102271515B (en) | 2008-10-31 | 2014-07-02 | 健泰科生物技术公司 | Pyrazolopyrimidine jak inhibitor compounds and methods |
CN102223885B (en) | 2008-11-24 | 2013-04-03 | 内尔维阿诺医学科学有限公司 | Cdk inhibitor for the treatment of mesothelioma |
HUE035769T2 (en) | 2009-02-12 | 2018-05-28 | Cell Signaling Technology Inc | Mutant ROS expression in human liver cancer |
AR077468A1 (en) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
JP5822844B2 (en) | 2009-12-21 | 2015-11-24 | サミュメッド リミテッド ライアビリティ カンパニー | 1H-pyrazolo [3,4-b] pyridine and therapeutic use thereof |
WO2011101408A1 (en) | 2010-02-18 | 2011-08-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for preventing cancer metastasis |
KR20130043104A (en) | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | Circulating biomarkers for disease |
US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
TWI510487B (en) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
US8543395B2 (en) | 2010-05-18 | 2013-09-24 | Shazam Entertainment Ltd. | Methods and systems for performing synchronization of audio with corresponding textual transcriptions and determining confidence values of the synchronization |
EP2918588B1 (en) | 2010-05-20 | 2017-05-03 | Array Biopharma, Inc. | Macrocyclic compounds as TRK kinase inhibitors |
WO2011156588A1 (en) | 2010-06-09 | 2011-12-15 | Dana-Farber Cancer Institute, Inc. | A mek 1 mutation conferring resistance to raf and mek inhibitors |
US9505829B2 (en) | 2010-08-19 | 2016-11-29 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
UY33597A (en) | 2010-09-09 | 2012-04-30 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US9783601B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
CN103492384B (en) | 2011-02-25 | 2016-05-11 | 诺华股份有限公司 | As compound and the composition of TRK inhibitor |
DK2712358T3 (en) | 2011-05-13 | 2017-02-06 | Array Biopharma Inc | PYRROLIDINYLUREA, PYRROLIDINYLTHIOUREA AND PYRROLIDINYLGUANIDE IN COMPOUNDS AS TRKA-KINASE INHIBITORS |
WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
AU2012339753A1 (en) | 2011-11-14 | 2014-06-19 | Tesaro, Inc. | Modulating certain tyrosine kinases |
CN104114553B (en) | 2011-12-12 | 2017-03-01 | 雷迪博士实验室有限公司 | Substituted pyrazolo [1,5 a] pyridine as tropomyosin receptor kinase (Trk) inhibitor |
EP2842955B1 (en) | 2012-04-26 | 2016-10-05 | ONO Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
PL3333166T3 (en) | 2012-05-23 | 2020-09-07 | Nerviano Medical Sciences S.R.L. | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
TWI585088B (en) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | Imidazo[1,2-b]pyridazine analogues as kinase inhibitors |
ES2600628T3 (en) | 2012-06-28 | 2017-02-10 | Johnson & Johnson Consumer Inc. | Racecadotril liquid composition |
EP2877598A1 (en) | 2012-07-24 | 2015-06-03 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
EP2689778A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
US20150218652A1 (en) | 2012-08-31 | 2015-08-06 | The Regents Of The Unversity Of Colorado, A Body Corporate | Methods for diagnosis and treatment of cancer |
US20140084039A1 (en) | 2012-09-24 | 2014-03-27 | Electro Scientific Industries, Inc. | Method and apparatus for separating workpieces |
JP2014082984A (en) | 2012-10-23 | 2014-05-12 | Astellas Pharma Inc | Method for detecting novel ntrk2 activating mutation |
US9969694B2 (en) | 2012-11-13 | 2018-05-15 | Array Biopharma Inc. | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
PT2922844T (en) | 2012-11-13 | 2018-04-02 | Array Biopharma Inc | N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
LT2920166T (en) | 2012-11-13 | 2016-12-12 | Array Biopharma, Inc. | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain |
WO2014078408A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9546156B2 (en) | 2012-11-13 | 2017-01-17 | Array Biopharma Inc. | N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors |
US9981959B2 (en) | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078417A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
JP2016502536A (en) | 2012-11-29 | 2016-01-28 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | Methods to prevent tumor metastasis, treat and prognose cancer, and identify drugs that are putative metastasis inhibitors |
US9127055B2 (en) | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
HUE042591T2 (en) | 2013-02-19 | 2019-07-29 | Ono Pharmaceutical Co | Trk-inhibiting compound |
EP2981613A4 (en) | 2013-02-22 | 2016-11-02 | Boris C Bastian | Fusion polynucleotides and fusion polypeptides associated with cancer and particularly melanoma and their uses as therapeutic and diagnostic targets |
WO2014134096A1 (en) | 2013-02-27 | 2014-09-04 | Oregon Health & Science University | Methods of treating cancers characterized by aberrent ros1 activity |
WO2014152777A2 (en) | 2013-03-15 | 2014-09-25 | Insight Genetics, Inc. | Methods and compositions for the diagnosis and treatment of cancers resistant to ros1 inhibitors |
WO2014150751A2 (en) | 2013-03-15 | 2014-09-25 | Novartis Ag | Biomarkers associated with brm inhibition |
JP2016515508A (en) | 2013-03-15 | 2016-05-30 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | Fusion protein and method thereof |
CN113337604A (en) | 2013-03-15 | 2021-09-03 | 莱兰斯坦福初级大学评议会 | Identification and use of circulating nucleic acid tumor markers |
CN105378110A (en) | 2013-04-17 | 2016-03-02 | 生命技术公司 | Gene fusions and gene variants associated with cancer |
CA2917735C (en) | 2013-07-11 | 2017-04-18 | Betta Pharmaceuticals Co., Ltd | Protein tyrosine kinase modulators and methods of use |
WO2015012397A1 (en) | 2013-07-26 | 2015-01-29 | 公益財団法人がん研究会 | Method for detecting ntrk3 fusant |
EP3027655B1 (en) | 2013-07-30 | 2019-08-21 | Blueprint Medicines Corporation | Ntrk2 fusions |
AU2014340398A1 (en) | 2013-10-24 | 2016-06-09 | Georgetown University | Methods and compositions for treating cancer |
JPWO2015064621A1 (en) | 2013-10-29 | 2017-03-09 | 公益財団法人がん研究会 | Novel fusion and detection method thereof |
EP3636650A1 (en) | 2014-01-24 | 2020-04-15 | Turning Point Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
RU2659068C1 (en) | 2014-02-05 | 2018-06-28 | Вм Онколоджи Ллк | Composition of compounds and ways of their application |
US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
KR101998461B1 (en) | 2014-05-15 | 2019-07-09 | 어레이 바이오파마 인크. | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor |
WO2015183837A1 (en) | 2014-05-27 | 2015-12-03 | Brian Haynes | Compositions, methods, and uses related to ntrk2-tert fusions |
US20170114415A1 (en) | 2014-05-30 | 2017-04-27 | The Regents Of The University Of Colorado, A Body Corporate | Activating ntrk1 gene fusions predictive of kinase inhibitor therapy |
RU2017106794A (en) | 2014-08-01 | 2018-09-03 | Фармасайкликс Элэлси | BIOMARKERS FOR FORECASTING DVKKL RESPONSE TO TREATMENT USING VTK INHIBITOR |
WO2016027754A1 (en) | 2014-08-18 | 2016-02-25 | 小野薬品工業株式会社 | ACID-ADDITION SALT OF Trk-INHIBITING COMPOUND |
TWI716362B (en) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | Antibody molecules to pd-l1 and uses thereof |
HUE061448T2 (en) | 2014-11-16 | 2023-07-28 | Array Biopharma Inc | Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
WO2016097869A1 (en) | 2014-12-15 | 2016-06-23 | Cmg Pharmaceutical Co., Ltd. | Fused ring heteroaryl compounds and their use as trk inhibitors |
CN104672121B (en) | 2015-02-16 | 2017-10-24 | 上海华默西医药科技有限公司 | The preparation method of 2R (2,5 difluorophenyl) pyrrolidine hydrochloride |
CR20230191A (en) | 2015-05-20 | 2023-07-06 | Dana Farber Cancer Inst Inc | SHARED NEOANTIGENS (Div. exp 2017-584) |
AU2016270321B2 (en) | 2015-05-29 | 2020-09-10 | Ignyta, Inc. | Compositions and methods for treating patients with RTK mutant cells |
PE20180329A1 (en) | 2015-06-01 | 2018-02-13 | Loxo Oncology Inc | METHODS TO DIAGNOSE AND TREAT CANCER |
AU2015101722A4 (en) | 2015-06-19 | 2016-05-19 | Macau University Of Science And Technology | Oncogenic ros1 and alk kinase inhibitor |
US9782400B2 (en) | 2015-06-19 | 2017-10-10 | Macau University Of Science And Technology | Oncogenic ROS1 and ALK kinase inhibitor |
GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
JP6871903B2 (en) | 2015-07-02 | 2021-05-19 | ターニング・ポイント・セラピューティクス・インコーポレイテッドTurning Point Therapeutics,Inc. | Chiral diallyl macrocyclic molecule as a modulator of protein kinase |
TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
WO2017127835A2 (en) | 2016-01-22 | 2017-07-27 | The Medicines Company | Aqueous formulations and methods of preparation and use thereof |
TW201733580A (en) | 2016-03-11 | 2017-10-01 | 小野藥品工業股份有限公司 | Treating agent for cancer having TrK inhibitor resistance |
JP7061602B2 (en) | 2016-04-04 | 2022-04-28 | ロクソ オンコロジー, インコーポレイテッド | (S) -N- (5-((R) -2- (2,5-difluorophenyl) -pyrrolidin-1-yl) -pyrazolo [1,5-a] pyrimidin-3-yl) -3-hydroxy Liquid formulation of pyrrolidine-1-carboxamide |
BR112018070017A2 (en) | 2016-04-04 | 2019-02-05 | Loxo Oncology Inc | Pediatric Cancer Treatment Methods |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
CN109475545A (en) | 2016-04-19 | 2019-03-15 | 埃克塞里艾克西斯公司 | Triple negative breast cancer treatment method |
WO2017201156A1 (en) | 2016-05-18 | 2017-11-23 | Duke University | Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab |
WO2017201241A1 (en) | 2016-05-18 | 2017-11-23 | Mark Reynolds | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide |
JOP20190092A1 (en) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF |
JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
EP3700576A1 (en) | 2017-10-26 | 2020-09-02 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
US20210023086A1 (en) | 2018-03-29 | 2021-01-28 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
-
2009
- 2009-10-21 KR KR1020117011561A patent/KR101634833B1/en active Protection Beyond IP Right Term
- 2009-10-21 SG SG2014004790A patent/SG196855A1/en unknown
- 2009-10-21 HU HUE18151233A patent/HUE057625T2/en unknown
- 2009-10-21 TW TW103132675A patent/TWI577680B/en not_active IP Right Cessation
- 2009-10-21 BR BRPI0919873A patent/BRPI0919873B8/en active IP Right Grant
- 2009-10-21 HU HUE13197815A patent/HUE030413T2/en unknown
- 2009-10-21 TR TR2018/07039T patent/TR201807039T4/en unknown
- 2009-10-21 RS RS20211578A patent/RS62869B1/en unknown
- 2009-10-21 NZ NZ592809A patent/NZ592809A/en unknown
- 2009-10-21 NO NO16166461A patent/NO3106463T3/no unknown
- 2009-10-21 UY UY0001032192A patent/UY32192A/en active IP Right Grant
- 2009-10-21 LT LTEP13197815.7T patent/LT2725028T/en unknown
- 2009-10-21 ES ES09740245.7T patent/ES2456346T3/en active Active
- 2009-10-21 TW TW107124940A patent/TWI670272B/en active
- 2009-10-21 DK DK18151233.6T patent/DK3372605T3/en active
- 2009-10-21 WO PCT/US2009/061519 patent/WO2010048314A1/en active Application Filing
- 2009-10-21 PL PL18151233T patent/PL3372605T3/en unknown
- 2009-10-21 HR HRP20211722TT patent/HRP20211722T1/en unknown
- 2009-10-21 KR KR1020167022867A patent/KR101784798B1/en active Protection Beyond IP Right Term
- 2009-10-21 SG SG10201914059WA patent/SG10201914059WA/en unknown
- 2009-10-21 SI SI200930889T patent/SI2350071T1/en unknown
- 2009-10-21 KR KR1020147029018A patent/KR101652189B1/en active IP Right Grant
- 2009-10-21 ES ES13197815.7T patent/ES2588504T3/en active Active
- 2009-10-21 UA UAA201106366A patent/UA106054C2/en unknown
- 2009-10-21 AU AU2009308465A patent/AU2009308465B2/en active Active
- 2009-10-21 ES ES18151233T patent/ES2900243T3/en active Active
- 2009-10-21 EP EP13197815.7A patent/EP2725028B1/en active Active
- 2009-10-21 KR KR1020187011433A patent/KR102037619B1/en active IP Right Grant
- 2009-10-21 DK DK16166461.0T patent/DK3106463T6/en active
- 2009-10-21 SI SI200932152T patent/SI3372605T1/en unknown
- 2009-10-21 ES ES16166461T patent/ES2669581T7/en active Active
- 2009-10-21 CA CA2741313A patent/CA2741313C/en active Active
- 2009-10-21 AR ARP090104042A patent/AR074052A1/en active IP Right Grant
- 2009-10-21 MX MX2011004204A patent/MX2011004204A/en active IP Right Grant
- 2009-10-21 PT PT97402457T patent/PT2350071E/en unknown
- 2009-10-21 RU RU2011120345/04A patent/RU2523544C2/en active
- 2009-10-21 SI SI200931843T patent/SI3106463T1/en unknown
- 2009-10-21 PL PL16166461T patent/PL3106463T6/en unknown
- 2009-10-21 PL PL09740245T patent/PL2350071T3/en unknown
- 2009-10-21 RS RS20180555A patent/RS57221B2/en unknown
- 2009-10-21 EP EP09740245.7A patent/EP2350071B1/en active Active
- 2009-10-21 TW TW098135670A patent/TWI458729B/en active
- 2009-10-21 LT LTEP18151233.6T patent/LT3372605T/en unknown
- 2009-10-21 ME MEP-2018-133A patent/ME03010B/en unknown
- 2009-10-21 RS RS20140151A patent/RS53247B/en unknown
- 2009-10-21 PT PT181512336T patent/PT3372605T/en unknown
- 2009-10-21 DK DK09740245.7T patent/DK2350071T3/en active
- 2009-10-21 CN CN2009801518250A patent/CN102264736B/en active Active
- 2009-10-21 HU HUE16166461A patent/HUE037716T2/en unknown
- 2009-10-21 SG SG10201900514RA patent/SG10201900514RA/en unknown
- 2009-10-21 MY MYPI2011001770A patent/MY169791A/en unknown
- 2009-10-21 US US13/125,263 patent/US8513263B2/en active Active
- 2009-10-21 PT PT161664610T patent/PT3106463T/en unknown
- 2009-10-21 PL PL13197815.7T patent/PL2725028T3/en unknown
- 2009-10-21 EP EP18151233.6A patent/EP3372605B1/en active Active
- 2009-10-21 LT LTEP16166461.0T patent/LT3106463T/en unknown
- 2009-10-21 KR KR1020177027624A patent/KR101853026B1/en active IP Right Grant
- 2009-10-21 TW TW105143120A patent/TWI639605B/en active
- 2009-10-21 PT PT131978157T patent/PT2725028T/en unknown
- 2009-10-21 JP JP2011533303A patent/JP5600111B2/en active Active
- 2009-10-21 DK DK13197815.7T patent/DK2725028T3/en active
- 2009-10-21 EP EP16166461.0A patent/EP3106463B3/en active Active
- 2009-10-21 CN CN201310379854.0A patent/CN103509017B/en active Active
- 2009-10-21 SI SI200931507A patent/SI2725028T1/en unknown
-
2011
- 2011-04-14 IL IL212341A patent/IL212341A0/en unknown
- 2011-04-19 CL CL2011000880A patent/CL2011000880A1/en unknown
- 2011-05-16 CR CR20110261A patent/CR20110261A/en unknown
- 2011-05-20 CO CO11062725A patent/CO6440551A2/en active IP Right Grant
-
2012
- 2012-01-31 HK HK12100876.5A patent/HK1160640A1/en unknown
-
2013
- 2013-07-16 US US13/943,590 patent/US8865698B2/en active Active
-
2014
- 2014-03-31 HR HRP20140309AT patent/HRP20140309T1/en unknown
- 2014-06-30 JP JP2014134304A patent/JP5832597B2/en not_active Expired - Fee Related
- 2014-07-02 HK HK14106634.3A patent/HK1193101A1/en unknown
- 2014-09-18 US US14/490,460 patent/US9447104B2/en active Active
- 2014-10-21 SM SM201400153T patent/SMT201400153B/en unknown
-
2015
- 2015-01-14 US US14/596,611 patent/US9127013B2/en active Active
- 2015-08-31 JP JP2015170033A patent/JP6105008B2/en active Active
- 2015-09-04 US US14/846,166 patent/US9676783B2/en active Active
-
2016
- 2016-08-24 CY CY20161100831T patent/CY1118199T1/en unknown
- 2016-09-18 IL IL247884A patent/IL247884B/en active IP Right Grant
- 2016-09-20 JP JP2016182689A patent/JP6431512B2/en not_active Expired - Fee Related
-
2017
- 2017-01-05 US US15/399,389 patent/US10005783B2/en active Active
-
2018
- 2018-01-03 US US15/860,948 patent/US10047097B2/en active Active
- 2018-05-14 HR HRP20180746TT patent/HRP20180746T4/en unknown
- 2018-05-18 CY CY20181100514T patent/CY1120260T1/en unknown
- 2018-07-25 US US16/044,653 patent/US10774085B2/en active Active
- 2018-08-29 RU RU2018131134A patent/RU2018131134A/en unknown
- 2018-09-24 AR ARP180102740A patent/AR112833A2/en not_active Application Discontinuation
- 2018-11-02 JP JP2018207330A patent/JP6788649B2/en active Active
-
2020
- 2020-03-10 NL NL301033C patent/NL301033I2/en unknown
- 2020-03-10 LT LTPA2020504C patent/LTC3106463I2/en unknown
- 2020-03-10 NO NO2020004C patent/NO2020004I1/en unknown
- 2020-03-11 LU LU00150C patent/LUC00150I2/fr unknown
- 2020-03-11 HU HUS2000006C patent/HUS000512I2/en unknown
- 2020-03-16 CY CY2020006C patent/CY2020006I2/en unknown
- 2020-09-14 US US17/020,461 patent/US11267818B2/en active Active
- 2020-10-18 IL IL278119A patent/IL278119B/en unknown
-
2021
- 2021-11-26 CY CY20211101031T patent/CY1124923T1/en unknown
-
2022
- 2022-09-09 US US17/941,367 patent/US20230234955A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201900514RA (en) | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors | |
MX364157B (en) | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS. | |
UA104731C2 (en) | P38 map kinase inhibitors | |
MX2009010728A (en) | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors. | |
MY159230A (en) | P38 map kinase inhibitors | |
MX2009004700A (en) | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors. | |
MY155719A (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
WO2008121687A3 (en) | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors | |
MY153727A (en) | Pyridazinone derivatives | |
ECSP088906A (en) | PIRAZOLO 1,5-a PYRIMIDINS | |
SA520412192B1 (en) | 5-(2-(2,5-Difluorophenyl)Pyrrolidin-1 -Yl)-3-(1h-Pyrazol-1-Yl)Pyrazolo[1,5-A]Pyrimidine Derivatives and Related Compounds as Trk Kinase Inhibitors for Treating Cancer | |
MX2009007682A (en) | 6-benzyl-2,3,4,7-tetrahydro-indolo [2, 3-c] quinoline compounds useful as pde5 inhibitors. | |
NZ630580A (en) | 6-(4-(1-amino-3-hydroxycyclobutyl)phenyl)-5-phenyl(furo,thieno or pyrrolo) [2, 3-d] pyrimidin-4-one derivatives for the treatment of cancer | |
RS20080197A (en) | Pyrazolo/4,3-d/pyrimidin-5-yl)derivative used as pde5 inhibitors | |
EA201100941A1 (en) | PRODUCTION 3- (3-PYRIMIDIN-2-ILBENZYL) -1,2,4-TRIAZOLO [4,3-B] -PIRYMIDINE | |
MX2010002096A (en) | Thiadiazinone derivatives. | |
EA201100967A1 (en) | DERIVATIVES 3- (3-PYRIMIDIN-2-ILBENZIL) -1,2,4-TRIAZOLO [4,3-B] Pyridazine | |
TH127211B (en) | The pyrazolo compound [1,5-a] pyrimidine was replaced as a TRK kinase inhibitor. |